MORRISVILLE, N.C.--(BUSINESS WIRE)--Worldwide Clinical Trials continues its international speaking engagement tour on Tuesday, October 10, 2017 at the Outsourcing in Clinical Trials (OCT) Nordics 2017 conference in Copenhagen, Denmark. Director of Global Patient Recruitment and Retention, Barbara Zupancic, will present “Improving Patient Recruitment and Engagement in Orphan Disease.” This is the latest presentation in the speaking tour company executives have engaged in to focus on helping prominent biotech, pharmaceutical and medical device companies improve CRO partnership value.
This message is particularly poignant for sponsors seeking value-driven partnerships with CROs as they focus on therapies that address rare and orphan disease. Today, it is estimated that 350 million people suffer from rare disease worldwide. And, while 326 new drugs have been approved by the FDA and brought to market for all rare disease patients combined during the first 25 years of the Orphan Drug Act (passed in 1983), 95% of rare diseases have not one single FDA-approved drug treatment. Worldwide Clinical Trials is helping sponsors shift this paradigm and accelerate their path to regulatory approval for rare and orphan disease treatments with a scientific, medically-driven approach to well-conducted clinical trials.
At OCT Nordics, Zupancic will draw upon this experience while reflecting on four relevant themes for CROs to consider when embarking on rare disease studies to ensure value from the strategic partnership:
- The complexities of clinical study recruitment and patient engagement in rare disease
- The design, implementation and challenges of rare disease patient recruitment and retention programs
- The emotional and social needs of caregivers to determine how they color the patient experience
- Improving recruitment and compliance, expanding geographic reach, accelerating trials and reducing cost
For more details:
- WHAT: Presentation: Improving Patient Recruitment and Engagement in Orphan Disease
- WHERE: Outsourcing in Clinical Trials (OCT) Nordics 2017
- WHEN: October 10th, 2017, Copenhagen, Denmark; 9:30 am CEST
- WHO: Barbara Zupancic, Director, Global Patient Recruitment and Retention, Worldwide Clinical Trials
Sponsors can gain uncommon access to Worldwide Clinical Trials experts:
- Ask a Worldwide Expert: https://www.worldwide.com/about-us/meet-the-experts/
- Tweet: @Worldwidetrials #UncommonCRO with your challenging question
- Follow us on Twitter: @worldwidetrials
- Find us on LinkedIn: https://www.linkedin.com/company/worldwide-clinical-trials-inc-
Join us at an upcoming 2017 international speaking tour engagement:
- Michael F. Murphy M.D., Ph.D., Chief Medical & Scientific Officer, will lead a roundtable discussion entitled, "Innovative Program Design," during the World Orphan Drug Congress (WODC) Europe 2017, on November 14, 2017 in Barcelona, Spain.
- Alexander Solodovnikov, Senior Clinical Operations Manager, will share perspective on “The Future of Clinical Research: Growth Opportunities and Obstacles Whilst Conducting Clinical Research in Russia,” on November 14, 2017 and will host an express seminar, “Clinical Trials Results Reporting Requirements; Documentation Specifics,” on November 15, 2017, at Clinical Trials Russia in Moscow, Russia.
- Mike Ryan, Senior Vice President, International Business Development, will participate in the interactive session entitled, “PCMG Oxford Debate: This house believes that strategic partnerships are not fit for purpose,” during Partnerships in Clinical Trials on November 29, 2017 in Amsterdam, Netherlands.
About Worldwide Clinical Trials
Worldwide Clinical Trials employs more than 1,600 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From Early Phase and Bioanalytical Sciences through Late Phase and post approval, we provide world-class, full-service drug development services. With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. For more information, visit Worldwide.com.